dc.contributor.author |
Chang T.C. |
|
dc.contributor.author |
Vong K. |
|
dc.contributor.author |
Yamamoto T. |
|
dc.contributor.author |
Tanaka K. |
|
dc.date.accessioned |
2022-02-09T20:37:10Z |
|
dc.date.available |
2022-02-09T20:37:10Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
1433-7851 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/169410 |
|
dc.description.abstract |
An emerging approach in the field of targeted drug delivery is the establishment of abiotic metal-triggered prodrug mechanisms that can control the release of bioactive drugs. Currently, the design of prodrugs that use abiotic metals as a trigger relies heavily on uncaging strategies. Here, we introduce a strategy based on the gold-catalyzed activation of a phenanthridinium-based prodrug via hydroamination under physiological conditions. To make the prodrug strategy biocompatible, a gold artificial metalloenzyme (ArM) based on human serum albumin, rather than the free gold metal complex, was used as a trigger for prodrug activation. The albumin-based gold ArM protected the catalytic activity of the bound gold metal even in the presence of up to 1 mM glutathione in vitro. The drug synthesized via the gold ArM exerted a therapeutic effect in cell-based assays, highlighting the potential usefulness of the gold ArM in anticancer applications. |
|
dc.relation.ispartofseries |
Angewandte Chemie - International Edition |
|
dc.subject |
antitumor agents |
|
dc.subject |
gold catalysts |
|
dc.subject |
metalloenzymes |
|
dc.subject |
phenanthridinium |
|
dc.subject |
prodrugs |
|
dc.title |
Prodrug Activation by Gold Artificial Metalloenzyme-Catalyzed Synthesis of Phenanthridinium Derivatives via Hydroamination |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
22 |
|
dc.relation.ispartofseries-volume |
60 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
12446 |
|
dc.source.id |
SCOPUS14337851-2021-60-22-SID85103562650 |
|